The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.
Open Access
- 1 December 1993
- journal article
- research article
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 4 (12) , 1317-1326
- https://doi.org/10.1091/mbc.4.12.1317
Abstract
Vascular endothelial growth factor (VEGF)mRNA undergoes alternative splicing events that generate four different homodimeric isoforms, VEGF121, VEGF165, VEGF189, or VEGF206. VEGF121 is a nonheparin-binding acidic protein, which is freely diffusible. The longer forms, VEGF189 or VEGF206, are highly basic proteins tightly bound to extracellular heparin-containing proteoglycans. VEGF165 has intermediate properties. To determine the localization of VEGF isoforms, transfected human embryonic kidney CEN4 cells expressing VEGF165, VEGF189, or VEGF206 were stained by immunofluorescence with a specific monoclonal antibody. The staining was found in patches and streaks suggestive of extracellular matrix (ECM). VEGF165 was observed largely in Golgi apparatus-like structures. Immunogold labeling of cells expressing VEGF189 or VEGF206 revealed that the staining was localized to the subepithelial ECM. VEGF associated with the ECM was bioactive, because endothelial cells cultured on ECM derived from cells expressing VEGF189 or VEGF206 were markedly stimulated to proliferate. In addition, ECM-bound VEGF can be released into a soluble and bioactive form by heparin or plasmin. ECM-bound VEGF189 and VEGF206 have molecular masses consistent with the intact polypeptides. The ECM may represent an important source of VEGF and angiogenic potential.Keywords
This publication has 45 references indexed in Scilit:
- Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cellsPublished by Elsevier ,2004
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Growth factor control of extracellular proteolysisCell Differentiation and Development, 1990
- A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contactCell, 1990
- Developmental expression of the endogenous TIMP gene and a TIMP-lacZ fusion gene in transgenic mice.Genes & Development, 1990
- Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimensInternational Journal of Cancer, 1990
- Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity.The Journal of cell biology, 1990
- Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta.The Journal of cell biology, 1989
- Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.Journal of Clinical Investigation, 1989